Uncategorized

Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial – CNBC

Posted on Author Comments Off on Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial – CNBC
  1. Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial  CNBC
  2. Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study  The Wall Street Journal
  3. Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal  MarketWatch
  4. Zepbound results in more weight loss than Wegovy in trial, Eli Lilly says  NBC News
  5. Zepbound leads to more weight loss than Wegovy, study finds  ABC News